NZ509646A - Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties - Google Patents

Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties

Info

Publication number
NZ509646A
NZ509646A NZ509646A NZ50964699A NZ509646A NZ 509646 A NZ509646 A NZ 509646A NZ 509646 A NZ509646 A NZ 509646A NZ 50964699 A NZ50964699 A NZ 50964699A NZ 509646 A NZ509646 A NZ 509646A
Authority
NZ
New Zealand
Prior art keywords
protein transferase
farnesyl protein
transferase inhibitors
properties
radiosensitizing properties
Prior art date
Application number
NZ509646A
Inventor
Ginckel Robert Franciscus Van
Wim Joanna Floren
David William Nd
Walter Boudewijn Leopo Wouters
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP19980204331 external-priority patent/EP0924958B1/en
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Priority claimed from PCT/EP1999/004545 external-priority patent/WO2000001411A1/en
Publication of NZ509646A publication Critical patent/NZ509646A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Described is the use of a farnesyl protein transferase inhibitor for the preparation of a pharmaceutical composition having radiosensitising properties for administration before during or after irradiation of a tumour for treating cancer, wherein the inhibitor is a compound of formula (I), (II) or (III).
NZ509646A 1998-07-06 1999-06-30 Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties NZ509646A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98202257 1998-07-06
EP19980204331 EP0924958B1 (en) 1997-12-19 1998-12-18 Directional hearing device
PCT/EP1999/004545 WO2000001411A1 (en) 1998-07-06 1999-06-30 Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties

Publications (1)

Publication Number Publication Date
NZ509646A true NZ509646A (en) 2004-02-27

Family

ID=27675831

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ509646A NZ509646A (en) 1998-07-06 1999-06-30 Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties

Country Status (3)

Country Link
NZ (1) NZ509646A (en)
UA (1) UA64796C2 (en)
ZA (1) ZA200100151B (en)

Also Published As

Publication number Publication date
ZA200100151B (en) 2002-01-07
UA64796C2 (en) 2004-03-15

Similar Documents

Publication Publication Date Title
AP1599A (en) Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties.
NZ514628A (en) Use of inhibitors for inducing cancer cell death and tumor regression
AU2001233726A1 (en) Farnesyl protein transferase inhibitors for treating breast cancer
MY117961A (en) Inhibitors of farnesyl protein transferase
MXPA05007352A (en) Diazepinoindole derivatives as kinase inhibitors.
WO2001064194A3 (en) Farnesyl protein transferase inhibitor combinations with camptothecin compounds
PL342614A1 (en) Anticarcinogenic drugs
MX9800945A (en) Use of griseofulvin for inhibiting the growth of cancers.
WO2002028381A3 (en) Methods of inducing cancer cell death and tumor regression
BR9814419A (en) "combination of benzocycloheptapyridine compounds and antineoplastic drugs for the treatment of proliferative diseases"
TW200510384A (en) Novel farnesyl protein transferase inhibitors as antitumor agents
IL140716A0 (en) Use of inhibitors of protein kinase c epsilon to treat pain
DK1276482T3 (en) combination chemotherapy
AU2001260445A1 (en) Triterpenoid derivatives
AU3919001A (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
NZ509646A (en) Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties
IL121440A0 (en) The use of 1,3,4,6-tetrahydroxy-helianthrone and its derivatives in photodynamic therapy and certain such novel derivatives
JO2361B1 (en) Farnesyl transferase inhibiting 1-2 annelated quinoline enantiomer
WO2000037065A3 (en) Endocrine therapy for breast cancer: combined treatment with tamoxifen plus alkyl pcdfs
NZ531109A (en) New mandelic acid derivatives and their use as thrombin inhibitors
IL164356A (en) Use of alpha- bromo or alpha-chloro acryloyl distamycin derivatives in the preparation of medicaments for treating cancer
MX2023009962A (en) Combined pharmaceutical composition containing cdk4/6 inhibitor and use thereof.
EP1547596A4 (en) Medicinal composition and method for treating malignant tumor and utilization thereof
WO1995024199A3 (en) Use of compounds which inhibit phosphatidic acid formation for the manufacture of a medicament for the treatment of cancer
NZ336321A (en) Use of benzothiophene (raloxifene) for treating breast cancer

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired